Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Addressing the challenges of drug approvals in Europe & the US and the value of clinical trials

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses challenges associated with drug approvals in multiple myeloma in Europe and the United States, commenting on several agents being explored, including melphalan flufenamide (melflufen), panobinostat and belantamab mafodotin. Dr Richardson highlights findings from several trials which investigated these agents, with some suggesting contradicting results, which has ultimately influenced the approval of these agents. Dr Richardson also explains the importance of further investigating these agents to provide more definitive answers and to see where they may fit in the myeloma treatment landscape. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Regeneron: Consultancy; GlaxoSmithKline: Consultancy; Secura Bio: Consultancy; Protocol Intelligence: Consultancy; AstraZeneca: Consultancy; Abbvie: Consultancy; Celgene/BMS: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Karyopharm: Consultancy, Research Funding; Sanofi: Consultancy; Oncopeptides: Consultancy, Research Funding.